Novartis AG's Kisqali (ribociclib; LEE011) was approved on March 13 as the second drug of its kind in the first-line setting for certain breast cancer patients in the US – and it could have competition from a third next year – so the company has packaged and priced its product to compete with Pfizer Inc.'s first-to-market Ibrance (palbociclib).
Both drugs and Eli Lilly & Co.'s Phase III candidate abemaciclib are cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The mechanism quickly became the frontline standard of care for post-menopausal women with hormone receptor (HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative advanced or metastatic breast cancer – the populations for which Kisqali and Ibrance are approved
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?